Navigation Links
Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Date:11/1/2010

//Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106439393';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

ABBOTT PARK, Ill. and WATERTOWN, Mass., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.  Initial 3-day and 4-week results suggest that ABT-450/r (ABT-450 with 100mg of ritonavir to support once-daily dosing) demonstrates potent antiviral activity in treatment-naïve adults.  Results show that more than 90 percent of patients (21 of 23) on study drug achieved HCV-RNA levels <25 IU/mL at four weeks. Results were presented today at the American Association for the Study of Liver Disease annual meeting in Boston.

Key findings:  

  • After three days, treatment with ABT-450/r alone resulted in statistically significant, 4-log mean reductions of HCV RNA, across the three dose ranges of ABT-450 (50mg, 100mg, 200mg, once-daily dosing) compared to placebo  
  • At week four, 91.3 percent (21 of 23) of patients receiving ABT-450/r in combination with standard of care (SOC) – pegylated alpha interferon and ribavirin (pegIFN/RBV) – achieved HCV-RNA <25 IU/ml
  • Safety appears consistent to that expected with SOC

  • "In spite of the progress that has been made in HCV treatment, limitations in efficacy remain with the current standard of care," Fred Poordad, M.D., chief of hepatology at the Liver Disease and Transplant
    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Abbott Again Recognized for Environmental Initiatives in Illinois
    2. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
    3. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
    4. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
    5. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
    6. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
    7. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
    8. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
    9. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
    10. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
    11. Abbott Declares 347th Consecutive Quarterly Dividend
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
    (Date:10/17/2014)... , October 17, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced ... Monitor : North American Automated External ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report ... 2008-2018 analyzes the market of devices ...
    (Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
    Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
    ... April 13, 2011 ThermoGenesis Corp. (NASDAQ: ... that process and store adult stem cells, said today that ... Central Drugs Standard Control Organization of India (CDSCO), allowing its ... care system used for the preparation of cell concentrates, including ...
    ... 2011 Medco Health Solutions, Inc. (NYSE: MHS ... a press release before the market opens on Thursday, April ... the release, management will hold a conference call to review ... ET.   To access the live conference ...
    Cached Medicine Technology:ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 2ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 3ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 4Medco Announces Date for Release of First-Quarter 2011 Financial Results 2
    (Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
    (Date:10/20/2014)... Akron, OH (PRWEB) October 20, 2014 ... new Assisted Living Center on Oct. 14. The $11 ... amenities and services, and a cooked-to-order kitchen with full-service ... forward Akron’s premier choice for first class Assisted Living ... groundbreaking. “Our residents deserve the highest quality of care ...
    (Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
    (Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
    Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
    ... 5 (HealthDay News) -- Simple precautions will help keep you ... the house for winter or put up holiday decorations, experts ... people were treated in U.S. emergency departments for holiday decorating-related ... 43 percent of those injuries were caused by falls from ...
    ... find out whether a new drug or treatment makes ... life, according to a commentary published online December 3rd ... . Instead, most trials now are designed to detect ... which may not be clinically meaningful, write Alberto Ocana, ...
    ... Dec. 3 (HealthDay News) -- New research explains why immune function ... HIV. In those cases, the virus has mutations that protect ... kill immune cells, explained the researchers at the Mayo Clinic in ... not all HIV is equally bad for the immune system, the ...
    ... nicotine during pregnancy leads to a decrease in adult ... the hippocampus of the offspring, according to new research ... Neuroscience 2010, the annual Society for Neuroscience meeting in ... a possible cause for behavioral problems such as attention-deficit ...
    ... Dec. 3 (HealthDay News) -- The impending extinction of ... an important buffer against the transmission of infectious disease, ... the U.S. National Science Foundation and National Institutes of ... U.S. Environmental Protection Agency, focused on how the loss ...
    ... 2010 (BRONX, NY) Nearly a quarter of Americans ... cancer mortality rates than urban and suburban areas. Among the ... of physicians practice in rural areas and almost 4 out ... from an urban area. Finding the time, transportation, ...
    Cached Medicine News:Health News:Assessing positive outcomes of phase III trials 2Health News:Nicotine exposure in pregnant rats puts offspring at risk for learning disabilities 2Health News:Species Extinctions May Spell Trouble for Human Health 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2
    ... wide Mini-Sub cell GT system for ... acids in agarose gels includes a ... electrodes, a 15 x 7 cm ... two casting gates, and two 1.5 ...
    ... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
    ... data for future generations. Most gels can be ... plate of our gel dryer, covering them with ... them to hold the cellophane flat. Tut's Tombs ... an open area somewhat larger than the gel ...
    ... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
    Medicine Products: